Erratum to: Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer

פריטים דומים

• Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer
  מאת: Yamamoto, Noboru, et al.
  יצא לאור: (2016)
• Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results
  מאת: Kato, Terufumi, et al.
  יצא לאור: (2017)
• Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib
  מאת: Azuma, Koichi, et al.
  יצא לאור: (2016)
• Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non–Small-Cell Lung Cancer: AF-001JP
  מאת: Tamura, Tomohide, et al.
  יצא לאור: (2017)
• Three‐year follow‐up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non‐small cell lung cancer: Pooled analysis of ONO‐4538‐05 and ONO‐4538‐06 studies
  מאת: Horinouchi, Hidehito, et al.
  יצא לאור: (2019)